tesetaxel
Small moleculeexperimental
Tesetaxel is an orally administered taxane being investigated as a chemotherapy agent for various types of cancer, including breast cancer, gastric cancer, colorectal cancer, and other solid tumors. It differs from other members of the taxane class in that it is administered orally, not intravenously. — Wikipedia
Clinical trial activity
18 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
13
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2004 (NCT00077077)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)O[C@@]12CO[C@@H]1CC[C@@]1(C)[C@@H]3O[C@H](CN(C)C)O[C@@H]3C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ncccc4F)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C- Mol. weight
- 881.99 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTesetaxel ↗
- ChEMBLCHEMBL2107787 ↗
Also known as
- dj927
- dj-927
- dj-927
- dj-927
- tesetaxel
- tesetaxel
- tesetaxel
- tesetaxel
- tesetaxel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04312282 | Phase 1 | Mar 6, 2020 | Odonate Therapeutics, LLC |
| NCT03952325 | Phase 2 | May 31, 2019 | Odonate Therapeutics, LLC |
| NCT03858972 | Phase 2 | Feb 5, 2019 | Odonate Therapeutics, LLC |
| NCT03326674 | Phase 3 | Dec 21, 2017 | Odonate Therapeutics, LLC |
| NCT01609127 | Phase 2 | May 1, 2012 | Cornell University, Genta |
| NCT01573468 | Phase 2 | Apr 1, 2012 | Genta, University of Texas at Houston |
| NCT01348009 | Phase 1/Phase 2 (Phase 2) | May 1, 2011 | Genta, Yonsei University |
| NCT01337310 | Phase 1 | Apr 1, 2011 | Genta |
| NCT01315431 | Phase 1 | Mar 1, 2011 | Genta, University of Tennessee |
| NCT01296243 | Phase 2 | Feb 1, 2011 | Cornell University, Genta |
| NCT01221870 | Phase 2 | Nov 1, 2010 | Cornell University, Genta |
| NCT01215877 | Phase 2 | Sep 1, 2010 | Cornell University, Genta |
| NCT01170975 | Phase 1 | Jun 1, 2010 | Davita Clinical Research, Genta |
| NCT01095120 | Phase 2 | Mar 1, 2010 | Genta, University of Texas at Houston |
| NCT01064713 | Phase 2 | Feb 1, 2010 | Genta, University of Texas at Houston |
| NCT01092585 | Phase 2 | Feb 1, 2010 | Genta, University of Texas at Houston |
| NCT00080834 | Phase 2 | Feb 1, 2004 | Daiichi, Daiichi Sankyo |
| NCT00077077 | Phase 1 | Feb 1, 2004 | Daiichi Sankyo |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genta | For profit | 12 | 11 | 2 | 2010 |
| Cornell University | Academic/Hospital | 4 | 0 | 1 | 2010 |
| Odonate Therapeutics, LLC | For profit | 4 | 4 | 3 | 2017 |
| University of Texas at Houston | Academic/Hospital | 4 | 1 | 1 | 2010 |
| Daiichi Sankyo | For profit | 2 | 2 | 2 | 2004 |
| Daiichi | For profit | 1 | 0 | 1 | 2004 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2010 |
| University of Tennessee | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2011 |
9 organizations
Page 1 / 1